A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) in the European Union Using Secondary Data Sources

19/05/2022
14/03/2024
EU PAS number:
EUPAS46910
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

A3921321 Protocol 11 Feb 2022

English (1.54 MB - PDF) View document
Updated protocol

A3921321_PROTOCOL- EU DUS_V5.0_11FEB2022

First published: 22/02/2024
English (1.8 MB - PDF) View document
Study results
Study report
Other information